Scott Applebaum

Scott Applebaum brings over two decades of legal, regulatory, and operational experience in the biopharmaceutical industry to VectivBio.

Prior to joining VectivBio, Mr. Applebaum was the Chief Legal & Compliance Officer and Senior Vice President of Regulatory Affairs at Trevena, where he played a key role in gaining FDA approval for their lead product, Olinvyk®️️️. Previously, he served as President of Context Therapeutics and was General Counsel at Vitae Pharmaceuticals, where he was instrumental in their sale to Allergan. Formerly, he was Chief Legal Officer for Medgenics, a rare genetic disease company. Mr. Applebaum spent 10 years at the Shire, where his roles included heading up their global legal group, managing their neuroscience portfolio outside of the United States as SVP of the Neuroscience Business Unit, and leading the implementation and execution of the regulatory strategy for all of Shire’s specialty pharmaceutical products worldwide as SVP of Global Regulatory Affairs, Quality Assurance, and Compliance. Previously, he was Senior Counsel for medicines and medical imaging at Bristol Myers Squibb.

Prior to his career in the biopharmaceutical industry, Mr. Applebaum was a lawyer at Dechert LLP. He received his J.D. from Stanford Law School and a B.S. in Economics, Finance, and Accounting from the University of Pennsylvania.